Table of Contents

company-logo

Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. Its products pipeline includes Budesolv for the treatment of allergic rhinitis and autoimmune gastritis; Tacrosolv, which is in Phase II clinical trial for anterior inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen that is in Phase I clinical trial for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.

Marinomed Biotech Dividend Announcement

• Marinomed Biotech does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Marinomed Biotech dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Marinomed Biotech Dividend History

Marinomed Biotech Dividend Yield

Marinomed Biotech current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Marinomed Biotech stock? Use our calculator to estimate your expected dividend yield:

Marinomed Biotech Financial Ratios

P/E ratio-1.89
PEG ratio-0.40
P/B ratio-1.10
ROE72.06%
Payout ratio0.00%
Current ratio1.87
Quick ratio1.46
Cash Ratio0.72

Marinomed Biotech Dividend FAQ

Does Marinomed Biotech stock pay dividends?
Marinomed Biotech does not currently pay dividends to its shareholders.
Has Marinomed Biotech ever paid a dividend?
No, Marinomed Biotech has no a history of paying dividends to its shareholders. Marinomed Biotech is not known for its dividend payments.
Why doesn't Marinomed Biotech pay dividends?
There are several potential reasons why Marinomed Biotech would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Marinomed Biotech ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Marinomed Biotech has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Marinomed Biotech a dividend aristocrat?
Marinomed Biotech is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Marinomed Biotech a dividend king?
Marinomed Biotech is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Marinomed Biotech a dividend stock?
No, Marinomed Biotech is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Marinomed Biotech stocks?
To buy Marinomed Biotech you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Marinomed Biotech stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.